Correction to “Immunological Impact of Oncolytic Adenoviruses on Cancer Therapy: Clinical Insights”

R. Nadafi, W. Dong, and V.W. van Beusechem, “Immunological Impact of Oncolytic Adenoviruses on Cancer Therapy: Clinical Insights,” European Journal of Immunology 55 (2025): e70024. After the online publication of the article, we found that Reference 67 was mistakenly included in the paragraph discussing ORCA-010, as it does not support the statement and the appropriate supporting references are currently missing from the manuscript. Therefore, the mentioned paragraph should contain the following references: An improved variant of Ad5-Δ24.RGD, ORCA-010, has been engineered to enhance both its safety and therapeutic efficacy [DOI: 10.1089/hum.2013.229]. In addition to the Ad5-Δ24 and RGD modifications, ORCA-010 includes a potency-enhancing T1 mutation [DOI: 10.1158/0008-5472.CAN-08-1145]. We apologize for this error.